latest
Market/Novel Tech Articles

Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc. have established a new RNAi collaboration for the development of ocular and CNS treatments

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), have announced a collaboration to “discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases” focused on ocular and central nervous system (CNS) indications. It is understood that Regeneron will pay a $400 million upfront payment to Alnylam and will […]

Read full story

Nightstar Therapeutics plc (Waltham, Mass. and London) is acquired by Biogen (Switzerland) for an estimated $877M

Nightstar Therapeutics plc,. (NASDAQ: NITE), has reported that an acquisition agreement with Biogen is to be completed in mid-year 2019 for an estimated $877M.  Nightstar was a UK based spin-out of the University of Oxford, based on the founding work of Professor Robert MacLaren at the Nuffield Laboratory of Ophthalmology.  The company recently announced the […]

Read full story

Spark Therapeutics (NASDAQ: ONCE) confirms that a definitive agreement will merge with Roche

Spark Therapeutics Inc,. has  reported that a definitive merger agreement with Roche to acquire Spark at a price of $114.50 per share in an all-cash transaction. As a result, Spark will have the value of approximately $4.8 billion on a fully diluted basis, inclusive of ~$500 million of projected net cash. The per share price […]

Read full story

Related Market/Novel Tech News